215 related articles for article (PubMed ID: 22577342)
1. Differential roles of uPAR in peritoneal ovarian carcinomatosis.
Al-Hassan NN; Behzadian A; Caldwell R; Ivanova VS; Syed V; Motamed K; Said NA
Neoplasia; 2012 Apr; 14(4):259-70. PubMed ID: 22577342
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
Knör S; Sato S; Huber T; Morgenstern A; Bruchertseifer F; Schmitt M; Kessler H; Senekowitsch-Schmidtke R; Magdolen V; Seidl C
Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):53-64. PubMed ID: 17891393
[TBL] [Abstract][Full Text] [Related]
3. ALG3 Promotes Peritoneal Metastasis of Ovarian Cancer through Increasing Interaction of α1,3-mannosylated uPAR and ADAM8.
Cui X; Pei X; Wang H; Feng P; Qin H; Liu S; Yan Q; Liu J
Cells; 2022 Oct; 11(19):. PubMed ID: 36231102
[TBL] [Abstract][Full Text] [Related]
4. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
5. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.
Jo M; Takimoto S; Montel V; Gonias SL
Am J Pathol; 2009 Jul; 175(1):190-200. PubMed ID: 19497996
[TBL] [Abstract][Full Text] [Related]
6. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
Chambers SK; Gertz RE; Ivins CM; Kacinski BM
Cancer; 1995 Apr; 75(7):1627-33. PubMed ID: 8826920
[TBL] [Abstract][Full Text] [Related]
7. Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.
Zhang J; Sud S; Mizutani K; Gyetko MR; Pienta KJ
Neoplasia; 2011 Jan; 13(1):23-30. PubMed ID: 21245937
[TBL] [Abstract][Full Text] [Related]
8. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
9. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.
Lutz V; Reuning U; Krüger A; Luther T; von Steinburg SP; Graeff H; Schmitt M; Wilhelm OG; Magdolen V
Biol Chem; 2001 May; 382(5):789-98. PubMed ID: 11517932
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms underlying postoperative peritoneal tumor dissemination may differ between a laparotomy and carbon dioxide pneumoperitoneum: a syngeneic mouse model with controlled respiratory support.
Matsuzaki S; Bourdel N; Darcha C; Déchelotte PJ; Bazin JE; Pouly JL; Mage G; Canis M
Surg Endosc; 2009 Apr; 23(4):705-14. PubMed ID: 18622550
[TBL] [Abstract][Full Text] [Related]
11. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
Borgfeldt C; Bendahl PO; Gustavsson B; Långström E; Fernö M; Willén R; Grenman S; Casslén B
Int J Cancer; 2003 Nov; 107(4):658-65. PubMed ID: 14520707
[TBL] [Abstract][Full Text] [Related]
12. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
Kaneko T; Konno H; Baba M; Tanaka T; Nakamura S
Cancer Sci; 2003 Jan; 94(1):43-9. PubMed ID: 12708473
[TBL] [Abstract][Full Text] [Related]
13. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
Pedersen N; Schmitt M; Rønne E; Nicoletti MI; Høyer-Hansen G; Conese M; Giavazzi R; Dano K; Kuhn W; Jänicke F
J Clin Invest; 1993 Nov; 92(5):2160-7. PubMed ID: 8227331
[TBL] [Abstract][Full Text] [Related]
14. Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells.
Lizalek J; McKenna T; Huegel K; Marsh S; Carolan A; Kobliska A; Heying E; Gardner N; Miller G; Kotecki A; Henningsen M; Lundt A; Farley J; Ellerbroek SM
Anticancer Res; 2015 Oct; 35(10):5263-70. PubMed ID: 26408685
[TBL] [Abstract][Full Text] [Related]
15. A Cross Talk between Neuronal Urokinase-type Plasminogen Activator (uPA) and Astrocytic uPA Receptor (uPAR) Promotes Astrocytic Activation and Synaptic Recovery in the Ischemic Brain.
Diaz A; Merino P; Manrique LG; Ospina JP; Cheng L; Wu F; Jeanneret V; Yepes M
J Neurosci; 2017 Oct; 37(43):10310-10322. PubMed ID: 28931568
[TBL] [Abstract][Full Text] [Related]
16. Normalization of the ovarian cancer microenvironment by SPARC.
Said N; Socha MJ; Olearczyk JJ; Elmarakby AA; Imig JD; Motamed K
Mol Cancer Res; 2007 Oct; 5(10):1015-30. PubMed ID: 17951402
[TBL] [Abstract][Full Text] [Related]
17. Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation.
Connolly BM; Choi EY; Gårdsvoll H; Bey AL; Currie BM; Chavakis T; Liu S; Molinolo A; Ploug M; Leppla SH; Bugge TH
Blood; 2010 Sep; 116(9):1593-603. PubMed ID: 20466854
[TBL] [Abstract][Full Text] [Related]
18. Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer: detection in ascitic fluid and localization to primary sites and metastatic implants.
Menzin AW; Loret de Mola JR; Bilker WB; Wheeler JE; Rubin SC; Feinberg RF
Cancer; 1998 Jan; 82(1):152-8. PubMed ID: 9428492
[TBL] [Abstract][Full Text] [Related]
19. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion.
Minopoli M; Botti G; Gigantino V; Ragone C; Sarno S; Motti ML; Scognamiglio G; Greggi S; Scaffa C; Roca MS; Stoppelli MP; Ciliberto G; Losito NS; Carriero MV
J Exp Clin Cancer Res; 2019 Nov; 38(1):459. PubMed ID: 31703596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]